Lycotec has published the first evidence that the French cheese, Roquefort, does not only inhibit inflammation associated with cardio- and cerebro-vascular diseases but also stimulates tissue regeneration.
Cambridge, UK (PRWEB UK) 29 May 2013
Recently Dr. Ivan Petyaev and Dr. Yuriy Bashmakov from Lycotec (http://www.lycotec.com/Home.html) published a hypothesis suggesting that regular consumption of Roquefort, Camembert and other fungal fermented cheeses could be behind the fact that, despite a diet high in saturated fats, the French have the lowest rate of cardio- and cerebro-vascular mortality.
Today the first discovery supporting this hypothesis has been revealed — http://www.hindawi.com/journals/tswj/2013/140591/.
In the latest edition of The Scientific World Journal Lycotec reported that their proprietary Roquefort extract could completely inhibit propagation of Chlamydia pneumonia, one of the most common bacteria populating our respiratory system, and the active form of which has long been associated with the development of heart attacks and strokes.
Moreover, this extract could inhibit inflammatory reactions caused by factors produced, for example, by other bacteria, which can be present and be responsible for imbalances and pathologies in other organs and tissues – from stomach and gastro-intestinal tract to skin.
The second striking factor reported in this article is that this Roquefort extract does not only suppress inflammation but also stimulate cells responsible for the initiation of tissue healing, their reparation and regeneration.
This discovery provides the first scientific evidence that Roquefort, and other fungal fermented cheeses, as a customary element of the French cuisine, could indeed contribute to the unique epidemiological paradox in this country.
Lycotec has already entered into partnership to set up a manufacturing production of these “blue cheese” extracts, which are already in demand by consumers and retailers for oral and skin topical application. This interest is coming from functional food & beverage, nutra-cosmetics, beauty and pharma industries.
The company expects that the first product with anti-inflammatory and regenerative extracts from “blue cheese” will be on the market later this year.
Meanwhile Lycotec is still undertaking more research to understand more about active molecules of these extracts, the mechanism of their actions and potential applicability to treat and prevent major modalities in human health.
About the Lycotec Team:
Based in Cambridge, Lycotec focuses on the development and commercialisation of its proprietary bio-medical technologies for pharmaceutical, nutraceutical and functional food industries.
For more information, please contact info(at)lycotec(dot)com.